Key points are not available for this paper at this time.
Because of quality control issues, the Sanofi spinoff EuroAPI will halt output of all active pharmaceutical ingredients (APIs) at its plant in Brindisi, Italy. The site produces 11 APIs and intermediates, most of which are anti-infectives such as spiramycin, rifaximin, rifampicin, and teicoplanin. Amid growing competition, EuroAPI announced earlier this year that it will stop making 13 money-losing APIs and close some European sites.
Aayushi Pratap (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: